Login / Signup

Is the fluoroquinolone combination necessary for empirical antibiotic regimen in severe community-acquired pneumonia?

Seungtak OhWooyoung JangBongyoung Kim
Published in: Postgraduate medicine (2024)
In patients with severe CAP, there were no differences in the clinical outcomes, including mortality, between the TZP and FQ combination therapy and TZP monotherapy. FQ combination was not significantly associated with in-hospital mortality.
Keyphrases
  • combination therapy
  • community acquired pneumonia
  • early onset
  • cardiovascular events
  • risk factors
  • randomized controlled trial
  • drug induced
  • clinical trial
  • open label
  • coronary artery disease
  • type diabetes